Neurogenesis-Targeting Therapies for Neurodegenerative Diseases
<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Neurogenesis-Targeting Therapies for Neurodegenerative Diseases</th>
</tr>
<tr>
<td class="label">Name</td>
<td><strong>Neurogenesis-Targeting Therapies for Neurodegenerative Diseases</strong></td>
</tr>
<tr>
<td class="label">Type</td>
<td>Therapeutic</td>
</tr>
</table>
Pathway Diagram
flowchart TD
N0["Neurogenesis"]
N1["BDNF"]
N1 -->|"activates"| N0
N2["Inflammation"]
N2 -->|"activates"| N0
N3["Neurodegeneration"]
N3 -->|"activates"| N0
N4["Als"]
N4 -->|"activates"| N0
N5["APOPTOSIS"]
N5 -->|"activates"| N0
N6["OXIDATIVE STRESS"]
N6 -->|"activates"| N0
N3 -->|"activates"| N0
N7["Depression"]
N7 -->|"activates"| N0
N8["Neuroinflammation"]
N8 -->|"activates"| N0
N7 -->|"activates"| N0
N2 -->|"activates"| N0
N9["CYTOKINES"]
N9 -->|"activates"| N0
Introduction
Neurogenesis Targeting Therapies For Neurodegenerative Diseases is a treatment approach for neurodegenerative diseases. This page provides comprehensive information about its mechanism of action, clinical evidence, and therapeutic potential.
Overview
...Neurogenesis-Targeting Therapies for Neurodegenerative Diseases
<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Neurogenesis-Targeting Therapies for Neurodegenerative Diseases</th>
</tr>
<tr>
<td class="label">Name</td>
<td><strong>Neurogenesis-Targeting Therapies for Neurodegenerative Diseases</strong></td>
</tr>
<tr>
<td class="label">Type</td>
<td>Therapeutic</td>
</tr>
</table>
Pathway Diagram
Mermaid diagram (expand to render)
Introduction
Neurogenesis Targeting Therapies For Neurodegenerative Diseases is a treatment approach for neurodegenerative diseases. This page provides comprehensive information about its mechanism of action, clinical evidence, and therapeutic potential.
Overview
Neurogenesis, the process of generating new [neurons](/entities/neurons) from neural stem cells, occurs primarily in two regions of the adult mammalian brain: the subventricular zone (SVZ) of the lateral ventricles and the subgranular zone (SGZ) of the dentate gyrus in the [hippocampus](/brain-regions/hippocampus). These neural stem cells (NSCs) can proliferate, differentiate, and integrate into existing neural circuits, offering potential for brain repair in neurodegenerative conditions. [@gage2000]
In neurodegenerative diseases, endogenous neurogenesis is often impaired or insufficient to compensate for progressive neuronal loss. Various factors contribute to this impairment: chronic neuroinflammation, oxidative stress, protein aggregate accumulation, and age-related decline in growth factor signaling. Neurogenesis-targeting therapies aim to overcome these barriers by: [@eriksson1998]
Enhancing neural stem cell activation through growth factor supplementation or small molecule agonists
Modulating the niche environment to support survival and differentiation of new neurons
Providing exogenous stem cells for transplantation
Protecting newly generated neurons from degenerative processesThe therapeutic goal is not merely to increase the number of new neurons, but to ensure their proper differentiation, migration, and functional integration into neural circuits relevant to each disease context. [@zhao2008]
Mechanisms of Action
Growth Factor-Based Approaches
- Brain-Derived Neurotrophic Factor (BDNF): Promotes neuronal survival and differentiation
- Fibroblast Growth Factor (FGF): Stimulates NSC proliferation
- Vascular Endothelial Growth Factor (VEGF): Supports neurovascular coupling
- Insulin-like Growth Factor (IGF-1): Enhances neurogenesis and neuronal maturation
Small Molecule Agonists
- Phosphodiesterase inhibitors: Enhance cAMP signaling to promote neurogenesis
- AMPA receptor modulators: Increase neuronal activity-dependent neurogenesis
- Notch pathway inhibitors: Push NSCs toward neuronal differentiation
Cell-Based Therapies
- Neural stem cell transplantation: Direct delivery of NSCs to affected brain regions
- Induced pluripotent stem cells (iPSCs): Patient-derived neurons for replacement therapy
Clinical Applications
Alzheimer's Disease
Neurogenesis targeting in AD focuses on the hippocampus, where neuronal loss contributes to memory impairment. Strategies include: [@kempermann2015]
- Exercise-induced neurogenesis enhancement
- Pharmacological approaches (e.g., antidepressive agents with neurogenic effects)
- Dietary interventions (e.g., caloric restriction, flavonoids)
Parkinson's Disease
In PD, neurogenesis approaches aim to replace dopaminergic neurons in the substantia nigra: [@sorrells2018]
- Subventricular zone stimulation
- Transplantation of dopamine-producing cells
- Growth factor delivery to support endogenous repair
Stroke Recovery
Post-stroke neurogenesis is naturally elevated, and therapeutic approaches aim to enhance this response:
- Exercise and rehabilitation
- Pharmacological enhancement of NSC migration to damaged areas
- Cell-based therapies for circuit reconstruction
See Also
- [Neural Stem Cell Therapy](/therapeutics/neural-stem-cell-therapy)
- [iPSC Therapy](/therapeutics/ipsc-therapy-neurodegeneration)
- [Neurotrophic Factors](/mechanisms/neurotrophic-factors)
- [Brain-Derived Neurotrophic Factor](/entities/bdnf)
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Huntington's Disease](/diseases/huntington-disease)
- [Stroke](/diseases/stroke)
External Links
- [Nature: Neurogenesis in the adult brain](https://www.nature.com/subjects/adult-neurogenesis)
- [NIH: Neural Stem Cell Research](https://stemcells.nih.gov/)
Background
The study of Neurogenesis Targeting Therapies For Neurodegenerative Diseases has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
References
[Unknown, Ming, G.L. & Song, H. (2011). Adult neurogenesis in the mammalian brain: significant answers and significant questions (2011)](https://pubmed.ncbi.nlm.nih.gov/21609825/)
[Unknown, Gage, F.H. (2000). Mammalian neural stem cells (2000)](https://pubmed.ncbi.nlm.nih.gov/10688983/)
[Eriksson, P.S. et al., (1998). Neurogenesis in the adult human hippocampus (1998)](https://pubmed.ncbi.nlm.nih.gov/9809557/)
[Zhao, C. et al., (2008). Mechanisms and functional implications of adult neurogenesis (2008)](https://pubmed.ncbi.nlm.nih.gov/18295581/)
Kempermann, G. et al., (2015). Neurogenesis in the adult hippocampus (2015)
[Sorrells, S.F. et al., (2018). Human hippocampal neurogenesis drops sharply in children to undetectable levels in adults (2018)](https://pubmed.ncbi.nlm.nih.gov/29513649/)From the [SciDEX Exchange](/exchange) — scored by multi-agent debate
- [Context-Dependent CRISPR Activation in Specific Neuronal Subtypes](/hypothesis/h-63b7bacd) — <span style="color:#81c784;font-weight:600">0.62</span> · Target: Cell-type-specific essential genes
- [Epigenetic Memory Reprogramming for Alzheimer's Disease](/hypothesis/h-29ef94d5) — <span style="color:#ffd54f;font-weight:600">0.55</span> · Target: BDNF, CREB1, synaptic plasticity genes
- [Metabolic Reprogramming via Coordinated Multi-Gene CRISPR Circuits](/hypothesis/h-827a821b) — <span style="color:#ffd54f;font-weight:600">0.53</span> · Target: PGC1A, SIRT1, FOXO3, mitochondrial biogenesis genes
- [Targeting Bacterial Curli Fibrils to Prevent α-Synuclein Cross-Seeding](/hypothesis/h-8b7727c1) — <span style="color:#81c784;font-weight:600">0.64</span> · Target: CSGA
- [Trinucleotide Repeat Sequestration via CRISPR-Guided RNA Targeting](/hypothesis/h-3a4f2027) — <span style="color:#ffd54f;font-weight:600">0.59</span> · Target: HTT, DMPK, repeat-containing transcripts
- [Hippocampal CA3-CA1 circuit rescue via neurogenesis and synaptic preservation](/hypothesis/h-856feb98) — <span style="color:#81c784;font-weight:600">0.73</span> · Target: BDNF
- [Vagal Afferent Microbial Signal Modulation](/hypothesis/h-ee1df336) — <span style="color:#81c784;font-weight:600">0.71</span> · Target: GLP1R, BDNF
- [Vocal Cord Neuroplasticity Stimulation](/hypothesis/h-e0183502) — <span style="color:#ffd54f;font-weight:600">0.48</span> · Target: CHR2/BDNF
Related Analyses:
- [Selective vulnerability of entorhinal cortex layer II neurons in AD](/analysis/SDA-2026-04-01-gap-004) 🔄
- [4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) 🔄
- [TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) 🔄
- [Astrocyte reactivity subtypes in neurodegeneration](/analysis/SDA-2026-04-01-gap-007) 🔄
- [Blood-brain barrier transport mechanisms for antibody therapeutics](/analysis/SDA-2026-04-01-gap-008) 🔄
Pathway Diagram
The following diagram shows the key molecular relationships involving Neurogenesis-Targeting Therapies for Neurodegenerative Diseases discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)